Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Erik Margolis"'
Autor:
Michael J. Donovan, Ronald F. Tutrone, Johan Skog, Christian Fischer, James M. McKiernan, Vasisht Tadigotla, Mikkel Noerholm, Gordon D. Brown, Erik Margolis, Alan W. Partin, Ballentine Carter, Phillipp Torkler
Publikováno v:
Prostate Cancer and Prostatic Diseases. 25:296-301
Background The ability to discriminate indolent from clinically significant prostate cancer (PC) at the initial biopsy remains a challenge. The ExoDx Prostate (IntelliScore) (EPI) test is a noninvasive liquid biopsy that quantifies three RNA targets
Autor:
Erik, Margolis, Gordon, Brown, Alan, Partin, Ballentine, Carter, James, McKiernan, Ronald, Tutrone, Phillipp, Torkler, Christian, Fischer, Vasisht, Tadigotla, Mikkel, Noerholm, Michael J, Donovan, Johan, Skog
Publikováno v:
Prostate cancer and prostatic diseases. 25(2)
The ability to discriminate indolent from clinically significant prostate cancer (PC) at the initial biopsy remains a challenge. The ExoDx Prostate (IntelliScore) (EPI) test is a noninvasive liquid biopsy that quantifies three RNA targets in urine ex
Autor:
Michael J. Donovan, Alan W. Partin, Gordon A. Brown, Mikkel Noerholm, Ballentine Carter, Johan Karl Olov Skog, Ronald F. Tutrone, James M. McKiernan, Vasisht Tadigotla, Phillipp Torkler, Erik Margolis
BACKGROUND The ability to discriminate indolent from clinically significant prostate cancer (PC) in the initial biopsy setting remains an important health issue. ExoDx Prostate(IntelliScore) (EPI), is a non-invasive exosome based liquid biopsy test t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b0b276ec2bb33670e3852e9b65bdee4
https://doi.org/10.21203/rs.3.rs-131551/v1
https://doi.org/10.21203/rs.3.rs-131551/v1